🇺🇸 FDA
Pipeline program

Anti-CD20-CAR-transduced T cells

TMMU-BTC-003

Phase 2 mab active

Quick answer

Anti-CD20-CAR-transduced T cells for Leukemia is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Leukemia
Phase
Phase 2
Modality
mab
Status
active

Clinical trials